News: Biogen Inc (BIIB.O)

BIIB.O on Nasdaq

386.22USD
4 May 2015
Change (% chg)

-- (+0.00%)
Prev Close
$386.22
Open
$389.45
Day's High
$393.89
Day's Low
$384.75
Volume
1,457,011
Avg. Vol
2,009,350
52-wk High
$480.18
52-wk Low
$278.10

Search Stocks
Select another date:

Fri, Apr 24 2015

US STOCKS-Nasdaq hits 15-year high, propelled by Amazon, Microsoft

* Amazon shares touch life high after revenue beats estimates

Biogen says Tecfidera sales slow, delays data readout on Alzheimer's drug

- Slowing sales of Biogen Inc's key oral multiple sclerosis (MS) drug Tecfidera and a delay in a data readout for its keenly watched Alzheimer's drug sent the company's stock down as much as 8 percent on Friday.

UPDATE 3-Biogen says Tecfidera sales slow, delays data readout on Alzheimer's drug

* Co delays key data readout - executives (Adds company, analyst comments on Alzheimer's drug data; Updates shares)

US STOCKS-Nasdaq hits 15-year high, propelled by Amazon, Microsoft

* Amazon shares touch life high after revenue beats estimates

Biogen 1st qtr profit jumps 71 pct as MS drug Tecfidera shines

April 24 - Biogen Inc reported a 71 percent rise in quarterly profit, driven by strong demand for its top-selling oral multiple sclerosis (MS) drug, Tecfidera.

Exclusive: Biogen shortens name, expands ambitions in Alzheimer's, ALS

NEW YORK - Biogen Idec Inc has seen its market value quadruple in three years to more than $100 billion on the back of its successful multiple sclerosis drugs. Now it has new ambitions in its sights. | Video

Biogen's Alzheimer's drug slows mental decline in early study

- An experimental drug from Biogen Idec Inc became the first Alzheimer's treatment to significantly slow cognitive decline and reduce what is believed to be brain-destroying plaque in patients with early and mild forms of the disease, according to a small study likely to reignite hopes of a treatment. | Video

UPDATE 1-Biogen's Alzheimer's drug slows mental decline in early study

March 20 - An experimental drug from Biogen Idec Inc became the first Alzheimer's treatment to significantly slow cognitive decline and reduce what is believed to be brain-destroying plaque in patients with early and mild forms of the disease, according to a small study likely to reignite hopes of a treatment.

US STOCKS-Wall St set for higher open as Nike provides lift

* Futures up: Dow 148 pts, S&P 15 pts, Nasdaq 36 pts (Adds quote, updates prices)

UPDATE 1-Dementia drug research aided by $100 mln venture capital fund

* Backers include British govt, GSK, J&J, Pfizer, Lilly, Biogen

Select another date:
Search Stocks